BioCentury | Feb 1, 2020
Product Development

Any chance left for safer opioids?

The future is looking bleak for new opioids. Between a pair of advisory committee meetings this month that delivered two blows to abuse-deterrent candidates, and the discontinuation of at least half of the newest market...
BC Extra | Dec 12, 2019
Company News

Dec. 11 Company Quick Takes: Kite, Alkermes, argenx, Reblozyl, Denovo-Sunesis

Kite submits BLA for CD19 CAR T in mantle cell  Kite Pharma Inc. submitted Wednesday a BLA to FDA for KTE-X19 to treat mantle cell lymphoma after reporting Phase II data at the American Society...
BC Extra | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal. The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain...
BC Extra | Oct 23, 2019
Company News

With MS approval looming, Alkermes restructures to seek sustainable profits

Alkermes expects cost savings from a newly announced restructuring, combined with payments due to the company upon the anticipated approval of a new MS therapy, will allow it to maintain profitability in the coming years....
BC Extra | Aug 30, 2019
Clinical News

Aug. 30 Clinical Quick Takes: Pharnext falls on FDA request for second Phase III study, plus Genentech, Novartis and Seqirus

Pharnext shares sag on regulatory slowdown  Shares of Pharnext S.A. (Euronext:ALPHA) lost €4.99 (41%) to €7.16 on Friday after the company said FDA advised it to conduct a second Phase III study of PXT3003 prior...
BC Extra | Jul 30, 2019
Company News

July 29 Company Quick Takes: Dupixent sales boost Sanofi; plus Twist, J&J, Alkermes and more

Despite multibillion dollar impairment, Sanofi beats on 2Q19 earnings  Sanofi (Euronext:SAN; NASDAQ:SNY) reported 2Q19 sales of €496 million from dermatitis and asthma drug Dupixent dupilumab, beating the Street's estimate of €411 million. The pharma also...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
BC Extra | Apr 25, 2019
Company News

Alkermes sinks after reporting Aristada sales miss

Alkermes shares fell $4.44 (13%) to $30.31 Thursday after the company reported quarterly sales of schizophrenia therapy Aristada that fell short of both its own guidance and analysts' expectations. The company attributed the shortfall to...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

A lack of acknowledgment by key stakeholders in the healthcare system that medications can treat opioid abuse, along with a fragmented reimbursement system, means that effective treatments aren’t getting to the majority of patients who...
BC Extra | Apr 10, 2019
Company News

U.S. fraud charges pummel Indivior shares

Indivior fell 75.90p (72%) to 30.05p on Wednesday after the U.S. Department of Justice indicted the company for allegedly defrauding providers and payers to increase prescriptions of its opioid dependence drug Suboxone sublingual film. Wednesday's...
Items per page:
1 - 10 of 624